Todd Krause is a partner and member of the firm’s Intellectual Property Litigation Group. Todd has over 25 years of experience successfully litigating patent cases for leading global pharmaceutical and biotechnology companies.

To help his clients succeed, Todd clearly defines their strategic objectives, develops compelling trial themes early in the case, focuses his teams on issues that truly matter, and distills complex issues down to clear, factfinder-friendly trial arguments. With a Ph.D. in biological sciences and a postdoctoral fellowship in the Department of Molecular and Human Genetics at Baylor College of Medicine, Todd brings a profound understanding of the scientific aspects of his cases.

Todd has guided teams in numerous Hatch-Waxman litigations (most involving blockbuster drugs) and a diverse range of matters in the life sciences industry, including small-molecule and biologic drugs, medical devices, gene amplification techniques, cell-based assays, veterinary vaccines, and recombinant nucleic acids and proteins.

Recognized as a leading figure in the patent and life sciences legal fields, Todd has earned accolades such as being named as a Hatch-Waxman Patent Litigation Star by LMG Life Sciences; named as an IP Star by Managing Intellectual Property; and recommended by the IAM Patent 1000 and The Legal 500. He remains actively involved in legal organizations, while contributing to the advancement of his clients’ industries.

Representative Experience

• Represented multinational biopharmaceutical company in patent litigation related to a treatment for an autoimmune disease.
• Represented global biopharmaceutical company in patent litigation related to a HIV treatment.
• Represented Avanos in patent litigation related to cooled radiofrequency ablation products.
• Represented Johnson & Johnson subsidiary Janssen Biotech, Inc. in Hatch-Waxman patent litigations and inter partes review proceedings related to prostate cancer drug Zytiga®.
• Represented Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc. in Hatch-Waxman patent litigations related to the blood-thinner Xarelto®.
• Represented international pharmaceutical company in patent litigation related to cancer immunotherapy.
• Represented global biopharmaceutical company in patent litigation involving genetic mutations, recombinant DNA and proteins, and cellular assays related to a brain disorder.
• Represented Johnson & Johnson subsidiary Janssen Pharmaceuticals, Inc. in Hatch-Waxman patent litigation related to Nucynta®, a drug for the treatment of pain.
• Represented Forest Laboratories Inc. in multidistrict Hatch-Waxman patent litigations involving the blood pressure reduction agent Bystolic®.
• Represented Sunovion Pharmaceuticals, Inc. in Hatch-Waxman patent litigation involving Xopenex HFA®, an inhalation aerosol used to treat the narrowing of airways by asthma and chronic obstructive pulmonary disease.
• Represented Schering Corporation and MSP Singapore (both now owned by Merck) in several Hatch-Waxman patent litigations involving the blockbuster cholesterol lowering drugs Vytorin® and Zetia®.
• Represented ConvaTec, Inc. in a patent action involving negative pressure wound healing devices.
• Represented Columbia University professor, Dr. Gertrude Rothschild in patent actions related to methods for making semiconductor materials.
• Represented Mycogen Corp. in patent action arising under 35 U.S.C. §291 of the patent laws that involved genetically modified plants.
• Represented Boehringer Ingelheim in patent litigations related to a veterinary vaccine.
• Represented Hoffmann-La Roche in patent litigation related to the Nobel Prize winning technology Polymerase Chain Reaction (“PCR”) and a polymerase (“Taq”) used in that technology.
• Represented Hoffmann-La Roche and Boehringer Ingelheim in patent litigations related to the use of cell-based assays for drug discovery.